Denise Cerqueira Paranaguá-Vezozzo
University of São Paulo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Hotspot
Dive into the research topics where Denise Cerqueira Paranaguá-Vezozzo is active.
Publication
Featured researches published by Denise Cerqueira Paranaguá-Vezozzo.
Journal of Clinical Gastroenterology | 2009
Luciana Kikuchi; Denise Cerqueira Paranaguá-Vezozzo; Aline Lopes Chagas; Evandro Sobroza de Mello; Venancio Avancini Ferreira Alves; Alberto Queiroz Farias; Ricardo Pietrobon; Flair José Carrilho
Background The aims of this study were to analyze the overall survival of patients with cirrhosis and small hepatocellular carcinoma (HCC) and identify independent pretreatment predictors of survival in Brazil. Methods Between 1998 and 2003, 74 patients with cirrhosis and small HCC were evaluated. Predictors of survival were identified using the Kaplan-Meier survival curves and the Cox model. Results The overall survival rates were 80%, 41%, and 17% at 12, 36, and 60 months, respectively. The mean length of follow-up after HCC diagnosis was 23 months (median 22 mo, range: 1 to 86 mo) for the entire group. Univariate analysis showed that model for endstage liver disease (MELD) score (P=0.016), Child-Pugh classification (P=0.007), α-fetoprotein level (P=0.006), number of nodules (P=0.041), tumor diameter (P=0.009), and vascular invasion (P<0.0001) were significant predictors of survival. Cox regression analysis identified vascular invasion (relative risk=14.60, confidence interval 95%=3.3-64.56, P<0.001) and tumor size >20 mm (relative risk=2.14, confidence interval 95%=1.07-4.2, P=0.030) as independent predictors of decreased survival. Treatment of HCC was related to increased overall survival. Conclusions Identification of HCC smaller than 20 mm is associated with longer survival. Presence of vascular invasion, even in small tumors, maybe associated with poor prognosis. Treatment of small tumors of up to 20 mm diameter is related to increased survival.
BMC Cancer | 2009
Jerônimo de Alencar Nogueira; Suzane Kioko Ono-Nita; Marcelo Eidi Nita; Marcelo Moreira Tavares de Souza; Eliane Pereira do Carmo; Evandro Sobroza de Mello; Cristovan Scapulatempo; Denise Cerqueira Paranaguá-Vezozzo; Flair José Carrilho; Venancio Avancini Ferreira Alves
BackgroundSer-249 TP53 mutation (249Ser) is a molecular evidence for aflatoxin-related carcinogenesis in Hepatocellular Carcinoma (HCC) and it is frequent in some African and Asian regions, but it is unusual in Western countries. HBV has been claimed to add a synergic effect on genesis of this particular mutation with aflatoxin. The aim of this study was to investigate the frequency of 249Ser mutation in HCC from patients in Brazil.MethodsWe studied 74 HCC formalin fixed paraffin blocks samples of patients whom underwent surgical resection in Brazil. 249Ser mutation was analyzed by RFLP and DNA sequencing. HBV DNA presence was determined by Real-Time PCR.Results249Ser mutation was found in 21/74 (28%) samples while HBV DNA was detected in 13/74 (16%). 249Ser mutation was detected in 21/74 samples by RFLP assay, of which 14 were confirmed by 249Ser mutant-specific PCR, and 12 by nucleic acid sequencing. All HCC cases with p53-249ser mutation displayed also wild-type p53 sequences. Poorly differentiated HCC was more likely to have 249Ser mutation (OR = 2.415, 95% CI = 1.001 – 5.824, p = 0.05). The mean size of 249Ser HCC tumor was 9.4 cm versus 5.5 cm on wild type HCC (p = 0.012). HBV DNA detection was not related to 249Ser mutation.ConclusionOur results indicate that 249Ser mutation is a HCC important factor of carcinogenesis in Brazil and it is associated to large and poorly differentiated tumors.
Pancreatology | 2009
Marianges Zadrozny Gouvêa da Costa; Dulce Reis Guarita; Suzane Kioko Ono-Nita; Jerônimo de Alencar Nogueira; Marcelo Eidi Nita; Denise Cerqueira Paranaguá-Vezozzo; Marcelo Moreira Tavares de Souza; Eliane Pereira do Carmo; Ana Cristina de Sá Teixeira; Flair José Carrilho
Introduction: Pancreas susceptibility to alcohol is variable and only 5–10% of chronic alcohol abusers develop chronic pancreatitis; the role of genetic factors in this process is unknown. The CFTR gene encodes a protein that acts on epithelial cells and plays a key role in normal exocrine pancreatic function. Methods: This study investigated the frequency of polymorphisms in intron 8 of the CFTR gene in patients with alcoholic chronic pancreatitis. Three groups of patients were studied: group A – 68 adult alcoholics with a diagnosis of chronic pancreatitis; group B – 68 adult alcoholics without pancreatic disease or liver cirrhosis and group C – 104 healthy nonalcoholic adults. Results: T5/T7 genotype was more frequent in group A (11.8%) than in group B (2.9%) (p = 0.0481), and there was no statistical difference when groups A and C (5.8%) were compared (p = 0.1317). The haplotype combination (TG)10-T7/(TG)11-T7 was more frequent in groups B (23.5%) and C (20.2%) than in group A (7.3%) (p = 0.0080 and 0.0162). Conclusion: There are differences when these three groups are compared and individuals with T5/T7 genotype might have a greater risk of developing chronic pancreatitis when they become chronic alcoholics.
Antiviral Therapy | 2013
Luciana Kikuchi; Aline Lopes Chagas; Regiane S. S. M. Alencar; Denise Cerqueira Paranaguá-Vezozzo; Flair José Carrilho
The global hepatocellular carcinoma (HCC) incidence is widely variable, depending on geographic region and the prevalence of major risk factors. In Brazil, two large multicentre retrospective studies were performed to investigate clinical and epidemiological aspects of HCC. In the first study, performed in 1997, HCC was found in cirrhotic livers in 71% of cases. Chronic alcoholism was present in 36% of cases, chronic hepatitis B in 35% and hepatitis C in 25%. In a 2010 survey, cirrhosis was present in 98% of cases and HCV was the main aetiology (54%). Differences in HBV prevalence were found among regions. Selection of HCC treatment depends on tumour burden, liver function and performance status. Liver transplantation (LT) is the best available curative treatment for HCC in its early stage and with compromised liver function. After modifications in priority policy, the number of patients with early HCC submitted for LT has increased in the past 5 years in Brazil. Chemoembolization is the most common initial HCC therapy in early and intermediate stages of HCC in Brazil.
Journal of clinical and translational hepatology | 2015
Karla Sawada Toda; Luciana Kikuchi; Aline Lopes Chagas; Ryan Yukimatsu Tanigawa; Denise Cerqueira Paranaguá-Vezozzo; Tulio Pfiffer; Manoel de Souza Rocha; Venâncio Avancini Ferreira Alves; Flair José Carrilho
Background and Aims: Schistosomiasis is a major chronic disease of humans in endemic regions, and infected individuals may develop a spectrum of pathology, including hepatic fibrosis, hepatosplenomegaly, and portal hypertension. Hepatocellular carcinoma (HCC) is considered the fifth most common cancer in the world, and there is limited and controversial evidence suggesting that Schistosoma mansoni infection may be a possible risk factor for HCC. The aim of this study was to report a case series of patients with HCC and S. mansoni infection and to conduct a literature review on the topic. Methods: From January 2002 to January 2015, an institutional database was screened retrospectively to identify patients with HCC and S. mansoni infection at a single center in the Department of Gastroenterology of University of São Paulo School of Medicine and Hospital das Clínicas, Brazil. Results: Seven cases were included. The mean age of patients was 62.1±10.3 years; six (85.7%) were male and one (14.3%) was female. All cases had positive epidemiology, coming from endemic areas of S. mansoni infection in Brazil, and four (57.1%) had previous complications (upper gastrointestinal bleeding) related to portal hypertension or surgery intervention (splenectomy) performed more than 10 years before the HCC diagnosis. Nontumoral portal vein thrombosis was identified in five (71.4%) patients. All patients had negative serology for HCV, and four (57.1%) had positivity of HBVcore antibodies without evidence of viral replication. According to BCLC staging, one (14.3%) patient was BCLC A and received TACE instead of RFA because HCC size was >30 mm; three (42.8%) BCLC B patients received sorafenib instead of local regional treatment due to the presence of nontumoral TPV. During follow-up, all patients developed tumoral progression and died. Conclusions: It remains unclear if S. mansoni infection alone has carcinogenic potential. The available literature indicates that S. Mansoni, in the presence of HBV and HCV infections, likely acts as a cofactor for the hepatic lesion and potentiates injury.
World Journal of Hepatology | 2017
Denise Cerqueira Paranaguá-Vezozzo; Adriana Ribas Andrade; Daniel Ferraz de Campos Mazo; Vinicius S. Nunes; Ana Luiza Vilar Guedes; Taisa Grotta Ragazzo; Renata Moutinho; Lucas Souto Nacif; Suzane Kioko Ono; Venâncio Avancini Ferreira Alves; Flair José Carrilho
AIM To determine the sensitivity and specificity of liver stiffness measurement (LSM) and serum markers (SM) for liver fibrosis evaluation in chronic hepatitis C. METHODS Between 2012 and 2014, 81 consecutive hepatitis C virus (HCV) patients had METAVIR score from liver biopsy compared with concurrent results from LSM [transient elastography (TE) [FibroScan®/ARFI technology (Virtual Touch®)] and SM [FIB-4/aspartate aminotransferase-to-platelet ratio index (APRI)]. The diagnostic performance of these tests was assessed using receiver operating characteristic curves. The optimal cut-off levels of each test were chosen to define fibrosis stages F ≥ 2, F ≥ 3 and F = 4. The Kappa index set the concordance analysis. RESULTS Fifty point six percent were female and the median age was 51 years (30-78). Fifty-six patients (70%) were treatment-naïve. The optimal cut-off values for predicting F ≥ 2 stage fibrosis assessed by TE were 6.6 kPa, for acoustic radiation force impulse (ARFI) 1.22 m/s, for APRI 0.75 and for FIB-4 1.47. For F ≥ 3 TE was 8.9 kPa, ARFI was 1.48 m/s, APRI was 0.75, and FIB-4 was 2. For F = 4, TE was 12.2 kPa, ARFI was 1.77 m/s, APRI was 1.46, and FIB-4 was 3.91. The APRI could not distinguish between F2 and F3, P = 0.92. The negative predictive value for F = 4 for TE and ARFI was 100%. Kappa index values for F ≥ 3 METAVIR score for TE, ARFI and FIB-4 were 0.687, 0.606 and 0.654, respectively. This demonstrates strong concordance between all three screening methods, and moderate to strong concordance between them and APRI (Kappa index = 0.507). CONCLUSION Given the costs and accessibility of LSM methods, and the similarity with the outcomes of SM, we suggest that FIB-4 as well as TE and ARFI may be useful indicators of the degree of liver fibrosis. This is of particular importance to developing countries.
Pancreas | 2016
Marianges Zadrozny Gouvêa da Costa; Julia Gloria Lucatelli Pires; Paulo Dominguez Nasser; Camila da Silva Ferreira; Ana Cristina de Sá Teixeira; Denise Cerqueira Paranaguá-Vezozzo; Dulce Reis Guarita; Flair José Carrilho; Suzane Kioko Ono
Objective This study aimed to investigate the association between chronic pancreatitis and smoking or genetic mutations. Methods The study sample comprised 148 patients with chronic pancreatitis, 110 chronic alcoholic subjects without pancreatic disease, and 297 volunteer blood donors. Results Of the patients with chronic pancreatitis, 74% had alcoholic etiology and 26% had idiopathic pancreatitis. The frequency of smoking was 91.4% in patients with alcoholic pancreatitis, higher than 73.3% in alcoholic subjects without pancreatitis (P < 0.01). The difference in smoking frequency was not significant between the patients with idiopathic pancreatitis and blood donors. The N34S mutation of serine peptidase inhibitor, Kazal type 1 (SPINK1) was found in 2.7% of patients with chronic alcoholic pancreatitis, in 5.3% of patients with idiopathic pancreatitis, and in 0.4% of blood donors (P = 0.02). The P55S mutation of SPINK1 was found in 2.7% of patients with alcoholic pancreatitis and in 0.7% of blood donors (P = 0.12). The R254W mutation of chymotrypsin C was found in 0.9% of patients with alcoholic pancreatitis, in 0.9% of chronic alcoholic subjects without pancreatitis, and in 0.4% of blood donors (P = 0.75). In all cases, the mutations were heterozygous. Conclusions Smoking and the N34S mutation of SPINK1 were positively correlated with chronic pancreatitis.
Hepatoma Research | 2018
Denise Cerqueira Paranaguá-Vezozzo; Celso Eduardo Lourenço Matielo; Daniel Ferraz de Campos Mazo; Lucas Souto Nacif; Mario G. Pessoa; Gleicy Pereira; Roque Gabriel Rezende de Lima; Patricia Momoyo Yoshimura Zitelli; Suzane Kioko Ono; Flair José Carrilho
Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including 93 patients: 31 with small diameter HCC and 62 without HCC. Groups were matched by age and gender. Multiple logistic regression analysis using Akaike Information Criteria to estimate the probability of HCC was performed. A model score was generated and bootstrap analysis was performed for internal validation. Results: Three significant laboratorial variables for HCC presence were found: alanine aminotransferase > 37 U/L [odds ratio (OR): 7.43 (1.61-34.19), P = 0.01], alpha-fetoprotein > 20 ng/mL [OR: 16.2 (4.17-63.01), P < 0.001] and platelet count < 100,000/mm [OR: 3.62 (1.43-9.14), P = 0.007]. A model score with an area under curve of 0.79 (95% CI: 0.7-0.89) was built based on these variables. The negative predictive value of those classified as at low risk of HCC was 99.1%. Conclusion: An easy and practical model score was generated. It may be an auxiliary tool for identification of HCV patients with low probability of small diameter HCC at initial evaluation composed of three serum examinations used in routine outpatient clinical practice.
Hepatology | 2018
Suzane Kioko Ono; Leda Bassit; Victor Van Vaisberg; Venâncio Avancini Ferreira Alves; Elia Garcia Caldini; Brian D. Herman; Reed S. Shabman; Nadia Fedorova; Denise Cerqueira Paranaguá-Vezozzo; Caroline Sampaio; Rafael Lages; Débora Raquel Benedita Terrabuio; Wellington Andraus; Raymond F. Schinazi; Flair José Carrilho
A 54-year-old male sought medical care with complaint of mild right hypochondrium abdominal pain lasting for 7 days with concomitant 3-day intermittent fever and 1-day nonpruritic maculopapular rash on torso and arms. One week before the onset of symptoms, the individual presented with aqueous diarrhea. Previous medical history included diabetes, rheumatoid arthritis, and large granular lymphocytic leukemia, for which he was treated with methotrexate, neutropenia, and past episodes of intermittent unconjugated hyperbilirubinemia attributed to Gilbert’s syndrome (homozygous for the thymine-adenine [TA]7TAA-allele). The patient was found to be dehydrated and febrile (38.38C). He appeared to have mild abdominal discomfort, with a positive rebound tenderness sign but a negative Murphy’s sign. Laboratory workup is shown in Table 1. Ultrasound and computed tomography findings were compatible with AAC (Fig. 1A,B). A comprehensive screening for infectious disease was conducted with negative results, but serum positive by polymerase chain reaction (RT-PCR) for ZIKV. Similarly, tests confirmed ZIKV in bile and gallbladder tissue by RT-PCR, with a 100% homology to a ZIKV sequence (see Supplementary Materials). The patient received empiric intravenous antibiotic therapy, including ceftriaxone (2 g/day) and metronidazole (2.25 g/day). Nonetheless, the patient’s general condition continued to deteriorate, and thus a laparoscopic cholecystectomy was performed. No Murphy’s sign developed during disease course. Surgical exploration (lasting 290 minutes) was difficult because of numerous adhesions and pericholecystic plastron. In addition, the patient was hyperthermic and hypotensive. Fluids and noradrenaline were administered and vital parameters stabilized. Intraoperative findings comprised an enlarged gallbladder with thickened walls and viscous bile inside with no calculi. Gallbladder histology revealed large portions of organizing
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) | 2018
Lucas Souto Nacif; Denise Cerqueira Paranaguá-Vezozzo; Alina Matsuda; Venancio Avancini Ferreira Alves; Flair José Carrilho; Alberto Queiroz Farias; Luiz Augusto Carneiro D’Albuquerque; Wellington Andraus
ABSTRACT Background: Liver elastography have been reported in hepatocellular carcinoma (HCC) with higher values; however, it is unclear to identify morbimortality risk on liver transplantation waiting list. Aim: To assess liver stiffness, ultrasound and clinical findings in cirrhotic patients with and without HCC on screening for liver transplant and compare the morbimortality risk with elastography and MELD score. Method: Patients with cirrhosis and HCC on screening for liver transplant were enrolled with clinical, radiological and laboratory assessments, and transient elastography. Results: 103 patients were included (without HCC n=58 (66%); HCC n=45 (44%). The mean MELD score was 14.7±6.4, the portal hypertension present on 83.9% and the mean transient elastography value was 32.73±22.5 kPa. The median acoustic radiation force impulse value of liver parenchyma was 1.98 (0.65-3.2) m/s and 2.16 (0.59-2.8) m/s in HCC group. The HCC group was significantly associated with HCV infection (OR 26.84; p<0.0001), higher levels of serum alpha-fetoprotein (OR 5.51; p=0.015), clinical portal hypertension (OR 0.25; p=0.032) and similar MELD score (p=0.693). The area under the receiver operating characteristics (AUROC) showed sensitivity and specificity for serum alpha-fetoprotein (cutoff 9.1 ng/ml), transient elastography value (cutoff value 9 kPa), and acoustic radiation force impulse value (cutoff value 2.56 m/s) of 50% and 86%, 92% and 17% and 21% and 92%, respectively. The survival group had a mean transient elastography value of 31.65±22.2 kPa vs. 50.87±20.9 kPa (p=0.098) and higher MELD scores (p=0.035). Conclusion: Elastography, ultrasound and clinical findings are important non-invasive tools for cirrhosis and HCC on screening for liver transplant. Higher values in liver elastography and MELD scores predict mortality.